PKTX News and Press, Protokinetix Inc From 02/19/20

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells th...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) recently filed for patent protection for a new application of its AAGP® molecule. During recent testing at The University of British Columbia, where photo receptors were transplante...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP®) molecule. We are shipping sufficient molecule to Iotron Industries in British Colum...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to date have shown no sign of irritation. About ITR Labora...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces the completion of an in vivo study to assess the effect of AAGP® on the long term survival and functional activity of photoreceptor precursor cells (PPCs) in the animal ocular...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces the initiation of a program testing AAGP®, to develop a potential therapy to treat Dry Eye Disease (DED). AAGP® has repeatedly demonstrated anti-inflammatory and cytoprotec...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) is pleased to provide the following updates regarding upcoming news in key areas. Current projects updates are expected from the following : Social Media: For more Company i...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ) updates shareholders regarding ongoing 3 rd stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the Co...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) has reached the mid-point of 3 rd stage of testing in retinal cell replacement therapy at the University of British Columbia. Functionality testing on experimental models three months post-tr...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP ® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment o...